# Ajai Chari

Source: https://onco.cc/people/ajai-chari/  
OnCo record `ajai-chari` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led the pivotal talquetamab trial, establishing GPRC5D as the second bispecific target in myeloma.

## Summary

Ajai Chari was principal investigator and first author of MonumenTAL-1, the trial that established the GPRC5DxCD3 bispecific talquetamab in relapsed myeloma and validated a target beyond BCMA. He has led studies of subcutaneous daratumumab, selinexor and real-world outcomes in myeloma and directs the myeloma programme at UCSF after many years at Mount Sinai.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: myeloma; bispecific; gprc5d
- Role: Director of the Multiple Myeloma Program, UCSF Helen Diller Family Comprehensive Cancer Center
- Specialisms: Multiple myeloma; Bispecific antibodies; GPRC5D-targeted therapy; Real-world outcomes

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Chari%20A%5BAuthor%5D%20talquetamab

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- targets: [CD3](https://onco.cc/targets/cd3/), [CD38](https://onco.cc/targets/cd38/), [GPRC5D](https://onco.cc/targets/gprc5d/)
- institutions: [UCSF Helen Diller Family Comprehensive Cancer Center](https://onco.cc/institutions/ucsf/)
- trials: [MonumenTAL-1](https://onco.cc/trials/monumental-1/)

---
JSON: https://onco.cc/api/v1/entities/ajai-chari.json